Differences in Aqueous Concentrations of Cytokines in Macular Edema Secondary to Branch and Central Retinal Vein Occlusion

Feng, Jing; Zhao, Tong; Zhang, Yan; Ma, Yan; Jiang, Yanrong

doi:10.1371/journal.pone.0068149

Cited by 52 publications

(38 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Анало-гичные изменения в стекловидном теле и влаге передней камеры также были описаны в ранее проводимых исследованиях [10,13,19,20,28].…”

Section: Discussionunclassified

“…Учитывая, что IL-6 -много-функциональный провоспалительный цитокин, повышение его концентрации при окклюзии вен сетчатки подтверждает его значение в иммуно-патогенезе данного заболевания, что также было отмечено некоторыми авторами [10,13].…”

Section: таблица 2 концентрация цитокинов в слезной жидкости на фонеunclassified

“…Исследования, посвященные изуче-нию уровня VEGF-A при окклюзии вен сетчатки, установили значительное превышение его кон-центрации при данном заболевании в сравнении с группой контроля, а также прямую корреляци-онную связь уровня VEGF-A от давления и кон-центрации кислорода в окружающих тканях [10,13,19,28]. Однако недостаточно изученной оста-ется зависимость концентрации VEGF-A от типа ретинальной венозной окклюзии и динамика на фоне специфической терапии.…”

Section: Introductionunclassified

“…Иммуно-химические исследования выявили повышение содержания интерлейкина-6 (IL-6) в жидких средах глаза у пациентов с окклюзией вен сет-чатки с прямой корреляцией от площади пора-жения [10,13,27]. Однако неясна зависимость концентрации IL-6 от степени гипоксии сетчат-ки и динамика на фоне проводимого лечения.…”

Section: Introductionunclassified

See 3 more Smart Citations

Studies of Systemic and Local Cytokine Level in Retinal Vein Occlusion Associated With Antiangiogenic Therapy

Дроздова¹,

Khokhlova²,

Мезенцева³

et al. 2018

Med. immunol.

View full text Add to dashboard Cite

Section: Discussionunclassified

Section: таблица 2 концентрация цитокинов в слезной жидкости на фонеunclassified

Section: Introductionunclassified

See 2 more Smart Citations

Studies of Systemic and Local Cytokine Level in Retinal Vein Occlusion Associated With Antiangiogenic Therapy

Дроздова¹,

Khokhlova²,

Мезенцева³

et al. 2018

Med. immunol.

View full text Add to dashboard Cite

“…High levels of VEGF have been found in the aqueous and vitreous from subjects with DR (Endo et al 2000), neovascular age-related macular degeneration (AMD) (Jonas et al 2012;Miao et al 2012;Muether et al 2013), retinal vein occlusion (RVO) (Feng et al 2013) and retinopathy of prematurity (ROP) (Velez-Montoya et al 2010). It has also been shown that IOP level as well as success rates of surgical intervention in NVG subjects were associated with the intraocular level of VEGF ).…”

Section: Discussionmentioning

confidence: 99%

Expression of cytokines on the iris of patients with neovascular glaucoma

Hou

Miao

Tao

et al. 2014

Acta Ophthalmologica

View full text Add to dashboard Cite

ABSTRACT.Purpose: To determine the expression levels of cytokines, including growth factors, inflammatory cytokines, and cell migration associated factors on the iris from subjects with neovascular glaucoma (NVG). Methods: After receiving formal consent from 12 subjects with NVG secondary to proliferative diabetic retinopathy and 12 subjects with primary open angle glaucoma (POAG), trabeculectomy was performed and iris specimens were collected during the surgery. Each subject with NVG received intravitreal injection of bevacizumab 1 week prior to the surgery. The mRNA level of vascular endothelial growth factor, basic fibroblastic growth factor, placentalinduced growth factor, interleukin-2, interleukin 6, tumour necrosis factor a, intercellular adhesion molecule 1 (ICAM-1) and integrin subunit a V were determined by real-time polymerase chain reaction. The mRNA levels were compared between the two groups. Results: The mRNA levels of all inflammatory cytokines and integrin subunit a V were significantly increased in the NVG group compared with POAG controls. However, the mRNA level of growth factors and ICAM-1 did not show any difference between the two groups. Conclusions: Inflammatory process maybe an important cause of iris neovascularization in subjects with NVG in addition to growth factors alone. Further studies should focus on the effect of growth factors in different phases in the pathogenesis of NVG.

show abstract

Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion

Braithwaite

Nanji²,

Lindsley

et al. 2014

Cochrane Database of Systematic Reviews

104

View full text Add to dashboard Cite

Background Central retinal vein occlusion (CRVO) is a relatively common retinal vascular disorder in which macular oedema may develop, with a consequent reduction in visual acuity. Until recently there has been no treatment of proven benefit, but growing evidence supports the use of anti-vascular endothelial growth factor (anti-VEGF) agents. Objectives To investigate the effectiveness and safety of anti-VEGF therapies for the treatment of macular oedema secondary to CRVO. Search methods We searched CENTRAL (which contains the Cochrane Central Register of Controlled Trials (CENTRAL) and the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2013, Issue 10), Ovid MEDLINE (January 1950 to October 2013), EMBASE (January 1980 to October 2013), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to October 2013), Cumulative Index to Nursing and Allied Health Literature (CINAHL) (January 1937 to October 2013), OpenGrey, OpenSIGLE (January 1950 to October 2013), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), Clinical-Trials.gov (www.clinicaltrials.gov), the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en) and Web of Science Conference Proceedings Citation Index-Science (CPCI-S). There were no language or date restrictions in the electronic search for trials. The electronic databases and clinical trials registers were last searched on 29th October 2013. Selection criteria We considered randomised controlled trials (RCTs) that compared intravitreal anti-VEGF agents of any dose or duration to sham injection or no treatment. We focused on studies that included individuals of any age or gender and a minimum of six months follow-up. Data collection and analysis Two review authors independently assessed trial quality and extracted data. The primary outcome was the proportion of participants with a gain in best-corrected visual acuity (BCVA) from baseline of greater than or equal to 15 letters (3 lines) on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart. Secondary outcomes included the proportion of participants with a loss of 15 letters or more of BCVA, the mean change from baseline BCVA, the mean change in central retinal thickness (CRT), the number and type of complications or adverse outcomes, and the number of additional interventions administered. Where available, we also presented quality of life and economic data. Main results We found six RCTs that met the inclusion criteria after independent and duplicate review of the search results. These RCTs included 937 participants and compared outcomes at six months to sham injection for four anti-VEGF agents: aflibercept (VEGF Trap-Eye, Eylea), bevacizumab (Avastin), pegaptanib sodium (Macugen) and ranibizumab (Lucentis). Three trials were conducted in Norway, Sweden and the USA, and three trials were multicentre, one including centres in the USA, Canada, India, Israel, Argentina and Columbia, a second including centres in the US...

show abstract

Differences in Aqueous Concentrations of Cytokines in Macular Edema Secondary to Branch and Central Retinal Vein Occlusion

Cited by 52 publications

References 32 publications

Studies of Systemic and Local Cytokine Level in Retinal Vein Occlusion Associated With Antiangiogenic Therapy

Studies of Systemic and Local Cytokine Level in Retinal Vein Occlusion Associated With Antiangiogenic Therapy

Expression of cytokines on the iris of patients with neovascular glaucoma

Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion

Contact Info

Product

Resources

About